Blake Pond

Deciphering Signaling Outcomes from a System of Complex Networks

M. Simon, I. Fraser, Madhusudan Natarajan, 2009, Science Signaling.

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

R. Collins, M. Konopleva, Z. Estrov, 2016 .

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

R. Collins, D. Bottomly, S. McWeeney, 2015 .

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

R. Collins, H. Kantarjian, J. Cortes, 2015 .